Christina Linke1, Karoline Ehlert2, Martina Ahlmann3, Birgit Fröhlich3, Daniela Mohring1, Birgit Burkhardt3, Claudia Rössig3, Andreas H Groll1. 1. Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany. 2. Department of Pediatric Hematology and Oncology, Children's Hospital, University Medicine Greifswald, Greifswald, Germany. 3. Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
Abstract
BACKGROUND: Epidemiology and management practices of invasive fungal diseases (IFD) after allogeneic haematopoietic stem cell transplantation (HSCT) are a subject of constant change. We investigated the contemporary incidence, diagnostics, antifungal management and outcome at a major paediatric transplant centre in Germany. METHODS: The single-centre retrospective observational study included all paediatric allogeneic HSCT patients (pts) transplanted between 2005 and 2015. Patient-related data were assessed up to 365 days post-transplant. The primary endpoint was the incidence of possible, probable and proven IFDs. Secondary endpoints included diagnostics and antifungal treatment; analysis of risk factors; and overall survival with the last follow-up in January 2017. RESULTS: A total of 221 first (196), second (21) or third (4) procedures were performed in 200 pts (median age: 9 years, range, 0.5-22) for leukaemia/lymphoma (149) and non-malignant disorders (72). Prophylaxis was administered in 208 HSCT procedures (94%; fluconazole, 116, mould-active agents, 92). At least one computed tomography scan of the chest was performed in 146, and at least one galactomannan antigen assay in 60 procedures. There were 15 cases of proven (candidemia, 4; aspergillosis, 4) or probable (aspergillosis, 7) IFDs, accounting for an incidence rate of 6.8%. Overall mortality at last follow-up was 30%; the occurrence of proven/probable IFDs was associated with a reduced survival probability (P < .001). CONCLUSION: Morbidity and mortality from IFDs at our institution were consistent with data reported from other centres. Utilisation of healthcare resources for prevention, diagnosis and management of IFDs was considerable.
BACKGROUND: Epidemiology and management practices of invasive fungal diseases (IFD) after allogeneic haematopoietic stem cell transplantation (HSCT) are a subject of constant change. We investigated the contemporary incidence, diagnostics, antifungal management and outcome at a major paediatric transplant centre in Germany. METHODS: The single-centre retrospective observational study included all paediatric allogeneic HSCT patients (pts) transplanted between 2005 and 2015. Patient-related data were assessed up to 365 days post-transplant. The primary endpoint was the incidence of possible, probable and proven IFDs. Secondary endpoints included diagnostics and antifungal treatment; analysis of risk factors; and overall survival with the last follow-up in January 2017. RESULTS: A total of 221 first (196), second (21) or third (4) procedures were performed in 200 pts (median age: 9 years, range, 0.5-22) for leukaemia/lymphoma (149) and non-malignant disorders (72). Prophylaxis was administered in 208 HSCT procedures (94%; fluconazole, 116, mould-active agents, 92). At least one computed tomography scan of the chest was performed in 146, and at least one galactomannan antigen assay in 60 procedures. There were 15 cases of proven (candidemia, 4; aspergillosis, 4) or probable (aspergillosis, 7) IFDs, accounting for an incidence rate of 6.8%. Overall mortality at last follow-up was 30%; the occurrence of proven/probable IFDs was associated with a reduced survival probability (P < .001). CONCLUSION: Morbidity and mortality from IFDs at our institution were consistent with data reported from other centres. Utilisation of healthcare resources for prevention, diagnosis and management of IFDs was considerable.
Authors: Sarah M Heston; Rebecca R Young; Hwanhee Hong; Ibukunoluwa C Akinboyo; John S Tanaka; Paul L Martin; Richard Vinesett; Kirsten Jenkins; Lauren E McGill; Kevin C Hazen; Patrick C Seed; Matthew S Kelly Journal: Open Forum Infect Dis Date: 2020-09-30 Impact factor: 3.835
Authors: Christopher C Dvorak; Brian T Fisher; Adam J Esbenshade; Michael L Nieder; Sarah Alexander; William J Steinbach; Ha Dang; Doojduen Villaluna; Lu Chen; Micah Skeens; Theoklis E Zaoutis; Lillian Sung Journal: J Pediatric Infect Dis Soc Date: 2021-04-30 Impact factor: 3.164
Authors: Miriam A Füller; Stefanie Kampmeier; Anna M Wübbolding; Judith Grönefeld; Almut Kremer; Andreas H Groll Journal: Support Care Cancer Date: 2022-05-19 Impact factor: 3.359